Low Molecular Weight Protein Nephrotoxicity
Low Molecular Weight Protein Nephrotoxicity
批准号:
8398973
负责人:
PAUL W. SANDERS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2015-03-31
关键词:
Acute Renal Failure with Renal Papillary NecrosisApoptosisApoptoticBindingCell SurvivalCell physiologyCellsChronic Kidney FailureClinicalComplexDepositionDiseaseEndocytosisEpithelial CellsEquilibriumEventFunctional disorderGenerationsGoalsHematologic NeoplasmsHydrogen PeroxideImmunoglobulinsIn VitroIncidenceInflammatoryInjuryKidneyKidney DiseasesKidney FailureLaboratoriesLaboratory StudyLeadLightMAP3K5 geneMediatingModalityMolecularMolecular WeightMorbidity - disease rateMultiple MyelomaOxidative StressPathogenesisPathologic ProcessesPatientsPeptidesPhosphotransferasesPopulationProcessProteinsPublishingRenal functionResearchRoleSRC geneSeminalSeriesSignal TransductionStreamStructure-Activity RelationshipSyndromeTestingTubular formationUMOD geneVeteransWorkdesignin vivomortalitynephrotoxicitynovelpreventresearch studyresponsetheoriestherapy design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Low Molecular Weight Protein Nephrotoxicity Significant advances have been made over the past twenty-five years in the characterization of tubulointerstitial renal injury caused by immunoglobulin free light chains (abbreviated FLC in this application) and in elucidation of the structure-function relationships involved in FLC-mediated tubular damage. The molecular pathogenesis has been described in some detail, increasing the potential to create novel treatments designed to interrupt pathological proceses and prevent progresive los of renal function related to deposition of monoclonal FLCs. Oxidative stres is a critical determinant of cell function and fate, especially in disease states. Published and preliminary studies from this laboratory demonstrated that endocytosis of FLCs generates hydrogen peroxide and induces intracellular oxidative stress that promotes renal epithelial cell activation and injury. The first aim will characterize further the effects of FLC on proximal tubular epithelial cell signaling events that lead to apoptosis or cell survival. The seminal observations that demonstrated the mechanism and functional significance of intraluminal cast formation have been published by this laboratory, and recent unpublished studies have provided critical proof of concept experiments that cast formation causes acute kidney injury and can be prevented with the use of a competitor peptide that binds to the FLC binding domain (LCBD) on Tamm-Horsfall protein (THP). These studies permit the singular focus of the second aim on the interactions of FLC with the LCBD on THP as the proximate cause of cast nephropathy. The overarching theory of this application is that tubulointerstitial renal damage from FLC is a complex process that involves both activation and injury of proximal tubular cells and intraluminal cast formation. These events can occur independently or synergize to produce the clinical syndromes of acute kidney injury and chronic kidney disease. Two aims will be pursued: Aim 1. Define the intracellular signaling events that are altered and effect cell survival following exposure of proximal tubular cells to FLC. The specific hypothesis to be tested is that endocytosis of FLCs into the proximal tubule activates c-Src (60-kDa product of c- src, also known as pp60c-src) and apoptosis signal-regulating kinase 1 (ASK1) signaling kinases, which activate downstream molecules that work in concert to balance cell survival and apoptosis. Aim 2. Define the molecular interaction between FLCs and the FLC binding domain (LCBD) on THP and the functional significance of this interaction. The hypothesis to be tested is that small molecular weight nonpeptide and peptide compounds effectively compete with FLC binding to the LCBD on THP and prevent cast nephropathy. The long-term goal of this project - understanding the molecular mechanisms involved in these processes - offers the potential to develop new treatments designed to ameliorate renal failure in the setting of overproduction of monoclonal FLC, such as multiple myeloma. !
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-Clinical Core
-
批准号:10746570
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2023
-
负责人:PAUL W. SANDERS
-
依托单位:
Vascular Mechanisms of Hypertensive Nephropathy
-
批准号:10533780
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:PAUL W. SANDERS
-
依托单位:
Vascular Mechanisms of Hypertensive Nephropathy
-
批准号:10363532
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:10041695
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:10578666
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:10295150
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:9778058
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8277784
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8696837
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8140851
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Mechanisms of Salt-Sensitive Hypertension and Hypertensive Nephrosclerosis
-
批准号:7903735
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2009
-
负责人:PAUL W. SANDERS
-
依托单位:
Core B - Resource for Pre-Clinical Studies of AKI
-
批准号:10252038
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Pilot and Feasibility Program
-
批准号:10456261
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Pilot and Feasibility Program
-
批准号:10252040
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Core B - Resource for Pre-Clinical Studies of AKI
-
批准号:10456259
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8733666
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8625443
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:9124659
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8899510
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
NITRIC OXIDE AND HEREDITARY LOW RENIN HYPERTENSION
-
批准号:2145379
-
项目类别:
-
资助金额:$15.84万
-
财政年份:1992
-
负责人:PAUL W. SANDERS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: